Progyny, Inc. (NASDAQ:PGNY – Get Free Report) has earned a consensus recommendation of “Hold” from the thirteen brokerages that are currently covering the stock, MarketBeat.com reports. Eight analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $25.42.
Several brokerages have weighed in on PGNY. Canaccord Genuity Group dropped their price objective on shares of Progyny from $18.00 to $17.00 and set a “hold” rating for the company in a research note on Wednesday, November 13th. BTIG Research downgraded shares of Progyny from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 7th. Canaccord Genuity Group downgraded Progyny from a “buy” rating to a “hold” rating and reduced their price target for the stock from $37.00 to $24.00 in a research report on Wednesday, August 7th. JMP Securities cut Progyny from an “outperform” rating to a “market perform” rating in a report on Thursday, September 19th. Finally, Jefferies Financial Group reduced their target price on Progyny from $31.00 to $24.00 and set a “buy” rating on the stock in a report on Thursday, September 19th.
Read Our Latest Analysis on Progyny
Institutional Investors Weigh In On Progyny
Progyny Stock Down 1.5 %
Shares of NASDAQ:PGNY opened at $13.77 on Friday. Progyny has a 12-month low of $13.39 and a 12-month high of $42.08. The business has a 50 day moving average of $17.30 and a 200-day moving average of $23.24. The stock has a market cap of $1.17 billion, a PE ratio of 23.74, a P/E/G ratio of 1.44 and a beta of 1.44.
Progyny (NASDAQ:PGNY – Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported $0.11 earnings per share for the quarter, missing the consensus estimate of $0.37 by ($0.26). Progyny had a return on equity of 11.36% and a net margin of 5.03%. The firm had revenue of $286.63 million for the quarter, compared to analyst estimates of $296.85 million. During the same period in the previous year, the business posted $0.16 earnings per share. The business’s revenue for the quarter was up 2.0% on a year-over-year basis. Equities research analysts expect that Progyny will post 0.64 earnings per share for the current year.
Progyny Company Profile
Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.
Recommended Stories
- Five stocks we like better than Progyny
- NYSE Stocks Give Investors a Variety of Quality OptionsĀ
- Warren Buffett, Cathie Wood Own Nu Holdings, Should You?
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- MercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?
- Energy and Oil Stocks Explained
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.